EOMES and neoplasm: Signaling through the TGF-β pathway can convert NK cells (CD49a−CD49b+Eomes+) into intermediate ILC1 (CD49a+CD49b+Eomes+) and bone fide ILC1 (CD49a+CD49b+Eomes+/−) within a tumor microenvironment.